Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma: Symptom burden and quality of life
Eikeland,S.A. Smeland,K.B. Mols,F. Fagerli,U. Bersvendsen,S. Kiserud,C.E. Fossa,A.
Eikeland,S.A.
Smeland,K.B.
Mols,F.
Fagerli,U.
Bersvendsen,S.
Kiserud,C.E.
Fossa,A.
Abstract
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin’s lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL). Material and methods A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population (n = 606). CIPN associated factors were identified by linear regression analysis. Results Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities (p < 0.001) and female gender (p = 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities (p < 0.001) and caseness (p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL (p < 0.001). Conclusion HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.
Description
Funding Information: This work was supported by the Norwegian Cancer Society and the DAM foundation, project number 2019/FO247426.
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue
Keywords
ASSOCIATION, Adverse effects, CANCER, COMORBIDITY, DISEASE, Hodgkin's lymphoma survivor, NEUROTOXICITY, POPULATION, QUESTIONNAIRE, STANDARD, SURVIVORS, VINCRISTINE, cancer survivorship, chemotherapy-induced peripheral neuropathy, SDG 3 - Good Health and Well-being
Citation
Eikeland, S A, Smeland, K B, Mols, F, Fagerli, U, Bersvendsen, S, Kiserud, C E & Fossa, A 2021, 'Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma : Symptom burden and quality of life', Acta Oncologica, vol. 60, no. 7, pp. 911-920. https://doi.org/10.1080/0284186X.2021.1917776